TY - JOUR
T1 - A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
AU - Muruato, Antonio E.
AU - Fontes-Garfias, Camila R.
AU - Ren, Ping
AU - Garcia-Blanco, Mariano A.
AU - Menachery, Vineet D.
AU - Xie, Xuping
AU - Shi, Pei Yong
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
AB - Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
UR - http://www.scopus.com/inward/record.url?scp=85089410039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089410039&partnerID=8YFLogxK
U2 - 10.1038/s41467-020-17892-0
DO - 10.1038/s41467-020-17892-0
M3 - Article
C2 - 32792628
AN - SCOPUS:85089410039
SN - 2041-1723
VL - 11
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 4059
ER -